Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa (PA) in the Lower Airways.

Trial Profile

Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa (PA) in the Lower Airways.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2014

At a glance

  • Drugs Aztreonam (Primary)
  • Indications Pseudomonal infections
  • Focus Adverse reactions; Registrational
  • Acronyms PALS
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Nov 2012 Planned End Date changed from 1 Jul 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 25 Oct 2012 Planned End Date changed from 1 Sep 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top